NZ601594A - Treatment of respiratory disorders - Google Patents

Treatment of respiratory disorders

Info

Publication number
NZ601594A
NZ601594A NZ601594A NZ60159411A NZ601594A NZ 601594 A NZ601594 A NZ 601594A NZ 601594 A NZ601594 A NZ 601594A NZ 60159411 A NZ60159411 A NZ 60159411A NZ 601594 A NZ601594 A NZ 601594A
Authority
NZ
New Zealand
Prior art keywords
respiratory disorders
acid
treatment
respiratory
disclosure relates
Prior art date
Application number
NZ601594A
Other languages
English (en)
Inventor
Wilson Caparros-Wanderley
Robin Mark Bannister
Gregory Stoloff
John Brew
Original Assignee
Biocopea Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1001912.3A external-priority patent/GB201001912D0/en
Application filed by Biocopea Ltd filed Critical Biocopea Ltd
Publication of NZ601594A publication Critical patent/NZ601594A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
NZ601594A 2010-02-05 2011-02-04 Treatment of respiratory disorders NZ601594A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1001912.3A GB201001912D0 (en) 2010-02-05 2010-02-05 Treatment of respiratory disorders
GB1015878A GB2477590A (en) 2010-02-05 2010-09-22 A non-steroidal anti-inflammatory drug (NSAID) formulation comprising a lipid carrier
PCT/GB2011/050189 WO2011095814A1 (en) 2010-02-05 2011-02-04 Treatment of respiratory disorders

Publications (1)

Publication Number Publication Date
NZ601594A true NZ601594A (en) 2014-10-31

Family

ID=43927856

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ601594A NZ601594A (en) 2010-02-05 2011-02-04 Treatment of respiratory disorders

Country Status (13)

Country Link
US (1) US20130178448A1 (enExample)
EP (1) EP2531188A1 (enExample)
JP (1) JP2013518869A (enExample)
CN (1) CN102858333A (enExample)
AU (1) AU2011212256A1 (enExample)
CA (1) CA2788766A1 (enExample)
GB (1) GB2477590A (enExample)
MX (1) MX2012009052A (enExample)
NZ (1) NZ601594A (enExample)
RU (1) RU2012137785A (enExample)
SG (2) SG183176A1 (enExample)
WO (1) WO2011095814A1 (enExample)
ZA (1) ZA201205829B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US9737500B2 (en) 2010-10-29 2017-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US8895537B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating cardiovascular diseases
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
GB201018289D0 (en) * 2010-10-29 2010-12-15 Biocopea Ltd Treatment of respiratory disorders
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
RU2016138830A (ru) * 2011-02-04 2018-12-12 ИнФёрст Хэлткэр Лимитед Составы и способы для лечения сердечно-сосудистых заболеваний
MX340951B (es) 2011-09-29 2016-07-29 Plx Pharma Inc Portadores dependientes del ph para la liberacion dirigida de productos farmaceuticos a lo largo del tracto gastrointestinal, composiciones de los mismos, y fabricación y uso de las mismas.
WO2013143688A1 (en) 2012-03-26 2013-10-03 Glatt Ag Taste-masked ibuprofen granules
CN103893171B (zh) * 2014-04-19 2016-05-25 武汉胜达康生物科技有限公司 盐酸苄达明在制备治疗或预防流感病毒感染药物中的应用
US20150343139A1 (en) * 2014-05-30 2015-12-03 Boston Scientific Scimed, Inc. Implantable pumps and related methods of use
AR102172A1 (es) 2015-10-05 2017-02-08 Química Luar S R L Una composición farmacéutica bactericida y virucida
CN109464670B (zh) * 2017-09-08 2022-08-02 中国科学院微生物研究所 调控a型和b型流感病毒核蛋白出核的关键氨基酸位点及其作为抗流感病毒药物靶点的用途
KR20220158031A (ko) 2020-03-26 2022-11-29 피엘엑스 옵코 인코포레이티드 pH 의존성 재구성이 가능한 제약 담체 및 그의 제조 및 사용 방법
US12324853B2 (en) 2020-08-10 2025-06-10 Quimica Luar S.R.L. Methods for treating respiratory viral infections
WO2022119756A1 (en) * 2020-12-04 2022-06-09 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for inhibiting m pro protease activity and for preventing and treating sars-cov-2 infection

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681897A (en) * 1984-01-16 1987-07-21 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
US4571400A (en) * 1984-12-18 1986-02-18 Belleview Pharmaceutical, Inc. Dihydrocodeine/ibuprofen pharmaceutical compositions and method
US4684666A (en) * 1986-08-19 1987-08-04 Haas Pharmaceuticals, Inc. Stabilized liquid analgesic compositions
CA1323306C (en) * 1987-03-05 1993-10-19 Mircea C. Popescu Pharmacological agent-lipid solution preparation
US5059626A (en) 1988-07-25 1991-10-22 Applied Analytical Industries, Inc. Liquid oral pharmaceutical compositions of non-steroidal anti-inflammatory drugs
US4918103A (en) * 1988-07-25 1990-04-17 Formulations Development Labs Liquid oral pharmaceutical compositions of non-steroidal anti-inflammatory drugs
US5011852A (en) * 1988-07-25 1991-04-30 Applied Analytical Industries, Inc. Liquid oral pharmaceutical compositions of non-steroidal anti-inflammatory drugs
US5552160A (en) * 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
ATE221379T1 (de) * 1991-05-01 2002-08-15 Jackson H M Found Military Med Verfahren zur behandlung infektiöser respiratorischer erkrankungen
JPH069381A (ja) * 1992-03-26 1994-01-18 Toyo Capsule Kk イブプロフェン含有軟カプセル剤
US5955451A (en) * 1995-05-12 1999-09-21 The University Of Texas System Board Of Regents Methods of enhancing the therapeutic activity of NSAIDS and compositions of zwitterionic phospholipids useful therein
AU6390096A (en) * 1995-07-20 1997-02-18 Pharmacia & Upjohn Company Stable clear solutions of non-steroidal anti-inflammatory drugs for incorporation into gelatin capsules
GB9625589D0 (en) * 1996-12-10 1997-01-29 Boots Co Plc Therapeutic agents
US6319513B1 (en) * 1998-08-24 2001-11-20 The Procter & Gamble Company Oral liquid mucoadhesive compounds
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
WO2002085414A2 (en) * 2000-12-19 2002-10-31 The Board Of Regents Of The University Of Texas System Nsaid formulations comprising lecithin oils for protecting the gastrointestinal tract and providing enhanced therapeutic activity
WO2002083105A2 (en) * 2001-04-10 2002-10-24 Zagros Pharma Inc. Composition for enhanced absorption of nsaids
US7960416B2 (en) * 2001-08-03 2011-06-14 Takeda Pharmaceutical Company Limited Stable emulsion composition
US20030232097A1 (en) * 2002-06-17 2003-12-18 Strides Inc. Oily wax matrix suspension formulation comprising ibuprofen free acid and potassium salt of ibuprofen
EP1539729A4 (en) * 2002-07-03 2008-02-20 Nitromed Inc NITROSED NON-TESTED OXIDE COMPOUNDS, COMPOSITIONS, AND APPLICATION METHODS
KR100507771B1 (ko) * 2002-11-08 2005-08-17 한미약품 주식회사 난용성 감기약 활성 성분의 경구투여용 조성물 및 그의제조 방법
PL1608407T3 (pl) * 2003-03-20 2006-12-29 Pharmacia Corp Dyspergowana kompozycja środka przeciw-zapalnego
EP1651210A1 (en) * 2003-07-31 2006-05-03 Pharmacia & Upjohn Company LLC Dispersible formulation of an anti-inflammatory agent
IL159729A0 (en) * 2004-01-06 2004-06-20 Doron I Friedman Non-aqueous composition for oral delivery of insoluble bioactive agents
AU2005206084A1 (en) * 2004-01-09 2005-08-04 Wyeth Microemulsions for pharmaceutical compositions
WO2006099325A2 (en) * 2005-03-10 2006-09-21 3M Innovative Properties Company Methods of treating ear infections
US20070092559A1 (en) * 2005-10-24 2007-04-26 Jinghua Yuan Liquid dosage forms having enteric properties of delayed and then sustained release
RU2009103000A (ru) * 2006-06-30 2010-08-10 МакНЕЙЛ-ППС, ИНК. (US) Твердые капсулы, наполненные жидкостью, содержащей ибупрофен
JP2008143807A (ja) * 2006-12-07 2008-06-26 Sato Pharmaceutical Co Ltd 感冒薬カプセル剤及びその製造方法
WO2009069139A1 (en) * 2007-11-28 2009-06-04 Alkem Laboratories Ltd. Dosage form providing an ibuprofen-containing liquid fill
JP2009155282A (ja) * 2007-12-27 2009-07-16 Kowa Co 固体分散体含有医薬組成物
CN102341125B (zh) * 2008-11-19 2014-02-12 梅里亚有限公司 包含头孢噻呋和酮洛芬或头孢噻呋和苯甲醇的配制剂
JP2012519159A (ja) * 2009-02-27 2012-08-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｄｅ４阻害剤及びｎｓａｉｄを含有する複合薬
WO2010097334A1 (de) * 2009-02-27 2010-09-02 Boehringer Ingelheim International Gmbh Arzneimittelkombinationen enthaltend pde4-inhibitoren und nsaids

Also Published As

Publication number Publication date
US20130178448A1 (en) 2013-07-11
GB2477590A (en) 2011-08-10
CA2788766A1 (en) 2011-08-11
SG183176A1 (en) 2012-09-27
AU2011212256A1 (en) 2012-08-23
SG10201500899VA (en) 2015-04-29
JP2013518869A (ja) 2013-05-23
CN102858333A (zh) 2013-01-02
EP2531188A1 (en) 2012-12-12
RU2012137785A (ru) 2014-03-10
GB201015878D0 (en) 2010-10-27
MX2012009052A (es) 2012-11-29
ZA201205829B (en) 2013-05-29
WO2011095814A1 (en) 2011-08-11

Similar Documents

Publication Publication Date Title
NZ601594A (en) Treatment of respiratory disorders
ES2906571T3 (es) Composiciones de soluciones sólidas para AINEs
US20080255209A1 (en) Combination of a NSAID and a PDE-4 inhibitor
BR112014025132A2 (pt) formulações de insulina
SA516380264B1 (ar) (s) -بيرليندول وأملاحه المقبولة صيدلانياً للاستخدام في الدواء
BR112015018200A2 (pt) composição mastigável para administração oral e processo para preparar a mesma
BR112012030485A2 (pt) composição para prevenção ou tratamento de osteoporose e processo de fabricação para a mesma
BR112013006541A2 (pt) agente preventivo ou terapêutico para fibrose
CN102186480A (zh) 包含6-二甲基氨基甲基-1-(3-甲氧基-苯基)-环己烷-1，3-二醇和非甾体抗炎药的药物合剂
CL2009002204A1 (es) Composicion intravenosa biocompatible que comprende un factor de coagulacion incluido en microparticulas de acido alginico o sales del mismo.
RU2016148182A (ru) (r)-пирлиндол и его фармацевтически приемлемые соли для применения в медицине
BR112015020261A2 (pt) composições farmacêuticas de dexmetilfenidato ou sais do mesmo de liberação modificada
AR063228A1 (es) Antinflamatorios no esteroideos contra la tos
SI2849747T1 (en) A pharmaceutical composition comprising (1r, 4r) -6'-fluoro-N, N-dimethyl-4-phenyl-4 ', 9'-dihydro-3'H-spiro [cyclohexane-1,1'-pyrano , 4, b) indol) -4-amine and NSAID
AR077297A1 (es) Medicamento para uso prolongado de nsaid
BR112013029790A2 (pt) composição farmacêutica compreendendo cetoprofeno
Bankar et al. Anti-hyperalgesic effect of paracetamol in rat model of thermal hyperalgesia: implications for the treatment of neuropathic pain.
BR112014027002A2 (pt) composição farmacêutica injetável de dexcetoprofeno e tramadol
LI et al. Clinical efficacy of tamsulosin hydrochloride sustained release tablets in treatment of premature ejaculation
Mohammed Babrak et al. Pain relief after arthroscopic knee surgery: a comparison of intra-articular ropivacaine, fentanyl, and dexmedetomidine: a prospective, double-blinded, randomized controlled study
CHANG et al. A case of Nicolau syndrome treated with non-steroidal anti-inflammatory drug injection therapy
WO2017060744A1 (en) Use of a combination of deramciclane and non-steroidal anti-inflammatory drugs to achieve improved anti-inflammatory effect
Noreen et al. Role of physical medicine and rehabilitation intervention for plantar fasciitis
CHEN et al. Clinical observation of danshen chuanxiongqin injection combined with flunarizine hydrochloride in the prevention of benign paroxysmal positional vertigo and lower extremity deep venous thrombosis in post-operative long-term bedridden patients with lower limb fractures
YANG et al. Clinical efficacy and safety of atorvastatin on atherosclerosis in advanced elderly patients

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: INFIRST HEALTHCARE LIMITED, GB

Effective date: 20141113

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 FEB 2016 BY OLCOTT

Effective date: 20150721

LAPS Patent lapsed